This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

The invention relates to 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) and bis(2,4,6-trinitrobenzoyl)oxalohydrazide, an energetic active mass comprising or consisting of 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) and/or bis(2,4,6-trinitrobenzoyl)oxalohydrazide, a use of 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) as explosive, a use of bis(2,4,6-trinitrobenzoyl)oxalohydrazide as explosive as well as methods for synthesizing 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) and bis(2,4,6-trinitrobenzoyl)oxalohydrazide.

The invention relates to 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) and bis(2,4,6-trinitrobenzoyl)oxalohydrazide, an energetic active mass comprising or consisting of 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) and/or bis(2,4,6-trinitrobenzoyl)oxalohydrazide, a use of 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) as explosive, a use of bis(2,4,6-trinitrobenzoyl)oxalohydrazide as explosive as well as methods for synthesizing 5,5-bis(2,4,6-trinitrophenyl)-2,2-bi(1,3,4-oxadiazole) and bis(2,4,6-trinitrobenzoyl)oxalohydrazide.

Provided are: a rubber additive that enables to provide a rubber composition having excellent low heat generation properties and manufacturing operability; a rubber composition including the rubber additive; and a pneumatic tire including the rubber composition. The rubber additive is characterized by containing a hydrazide compound represented by Formula (I) below, where R represents a hydroxyl group, an alkyl group having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms and A represents an alkylene group having 1 to 4 carbon atoms or an alkenylene group having 2 to 4 carbon atoms; the rubber composition containing the rubber additive; and the pneumatic tire including the rubber composition:

##STR00001##

The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.

The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.